In a recent retrospective analysis of the pan-cancer MSKCC-IMPACT patient cohort, Samstein et al.38 identified clinical benefit in 44% of patients with BRCA2-deficient cancers following ICB treatment. This evidence concerns the gene BRCA2 and cancer.